Latest news with #Indegene
Business Standard
12-07-2025
- Business
- Business Standard
Indegene launches NEXT Medical Writing Automation
Indegene has announced the launch of NEXT Medical Writing Automation to accelerate the creation of high-quality documents across clinical development, regulatory submissions, and beyond. NEXT Medical Writing Automation, an advanced platform that combines deep medical writing expertise with generative AI (GenAI). Purpose-built by experienced medical writers, NEXT Medical Writing Automation operates within familiar environments like Microsoft Word, auto-generating compliant drafts that adapt to diverse sponsor formats and workflows. It integrates seamlessly with Regulatory Information Management (RIM) systems, maintaining traceability and consistency across documents. NEXT Medical Writing Automation combines Indegenes decades of domain knowledge with the power of its AI engine, Cortex. Sameer Lal, SVP, Enterprise Medical Solutions, Indegene, said, With automated scheduling, intelligent task assignments, and robust data flow integration, NEXT Medical Writing Automation helps life sciences organizations scale operations efficiently while maintaining a strong compliance backbone. As document requirements grow and scrutiny intensifies, such solutions become essential to sustaining operational excellence. We see this platform as more than automationits about elevating the entire practice of medical writing. Writers can now focus on strategic tasks and critical thinking, while the platform manages the heavy lift of data and formatting. Indegene is a digital-first life sciences commercialization company that partners with biopharmaceutical, emerging biotech, and medical device companies to develop products, bring them to market, and enhance their impact throughout the product lifecyclemore effectively, efficiently, and in a modern, technology-driven manner. The companys consolidated net profit jumped 24.1% to Rs 117.60 crore on 12.3% increase in net sales to Rs 755.60 crore in Q4 FY25 over Q4 FY24. The scrip declined 1.02% to settle at Rs 564.35 on the BSE.
Business Upturn
03-07-2025
- Business
- Business Upturn
Indegene partners with FAST India to boost India's biotech ecosystem
By Aman Shukla Published on July 3, 2025, 10:40 IST FAST India, a non-profit organisation dedicated to advancing science and technology, has entered into a strategic, long-term partnership with Indegene to strengthen India's biotech and innovation ecosystem. This collaboration aims to scale research efforts and foster deeper collaboration between academia and the industry, creating a solid foundation for grassroots innovation. FAST India is actively working to position the country among the top three global science and technology leaders in the next decade. The organisation runs key initiatives such as the India Science Festival, national-level science competitions, and platforms that highlight cutting-edge R&D from India and abroad. The partnership will also support translational science and facilitate industry-academia connections through curated research, case studies, and insights. FAST India's surveys and reports, especially those focused on students and young professionals, will play a key role in understanding public interest and shaping policies that support scientific growth. This alliance is expected to play a pivotal role in accelerating India's progress in biotechnology and innovation. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Hans India
16-06-2025
- Business
- Hans India
Bengaluru ranks 14th among world's top startup ecosystems
Bengaluru: Bengaluru, the capital of Karnataka and India's leading tech hub, has been ranked 14th in the world in the list of top 20 startup ecosystems, according to the Global Startup Ecosystem Report (GSER) 2025 by Startup Genome. The city has jumped seven places from its 21st rank last year, marking the biggest leap among the top 20 global startup cities. Bengaluru is also the highest-ranked Indian city in the report, ahead of Delhi (29th) and Mumbai (40th). Globally, Silicon Valley continues to hold the top position, followed by New York and London in second and third place, respectively. Bengaluru has also been ranked 5th among the top 50 cities in the Artificial Intelligence (AI) sector, reflecting its growing strength in deep tech and innovation. The GSER report highlighted the success of Indian startups in 2024, especially Bengaluru-based ventures, with several high-value IPOs like Indegene Rs 1.11 lakh crore, Swiggy Rs 96,000 crore, GoDigit Rs 30,000 crore and Blackbuck Rs 8,600 crore. These successful listings delivered significant returns to early investors and further boosted India's reputation as a thriving startup nation. The report credited Karnataka government's support for the deep tech ecosystem as one of the reasons behind Bengaluru's rise in global experts believe this global recognition will attract more investors, talent, and innovation to the city, strengthening its position as a leading startup hub in Asia.
Economic Times
05-06-2025
- Business
- Economic Times
Sunil Singhania picks stake in Indegene, stock up 4%
Indegene shares: Sunil Singhania's fund acquired a stake in the company via a significant block deal. Synopsis Indegene shares: Abakkus was one of several institutional investors that participated in the transaction through which private equity giant Carlyle Group fully exited its 10.2% stake in the digital healthcare company. Shares of Indegene Ltd rose as much as 3.7% to Rs 611.50 on the BSE on Thursday, a day after Sunil Singhania's Abakkus Emerging Opportunities Fund picked up a stake in the company through a large block deal. Abakkus was among several institutional investors that bought shares in the transaction where private equity major Carlyle Group exited its entire 10.2% holding in the digital healthcare firm. ADVERTISEMENT A total of 2.53 crore shares, amounting to 10.56% of Indegene's equity, changed hands on Wednesday, June 4, at an average price of Rs 591 apiece, according to exchange data released Thursday. Carlyle, through its unit CA Dawn Investments, was the sole seller in the deal, garnering Rs 1,447 crore from the divestment. Alongside Abakkus, other buyers included East Bridge Capital Master Fund, Societe Generale, Smallcap World Fund, and Premji Invest's affiliate PI Opportunities AIF V. Together, these investors picked up 1.06 crore shares, or 4.42% stake, for Rs 627 crore. The shares were acquired in the price range of Rs 591–591.48 each. Details of other buyers were not available on the National Stock Exchange as of exit marks the end of a four-year investment in Indegene. The global private equity firm had invested $122 million (Rs 917 crore) in April 2021, purchasing 4.55 crore shares at Rs 201 apiece. ADVERTISEMENT Since then, it has sold shares in phases, first during Indegene's IPO in May 2024 at Rs 452 apiece, then at Rs 618 in December 2024, and finally at around Rs 591 this week. The investment delivered an internal rate of return of 31% for Carlyle, underscoring the strong returns possible in India's digital healthcare shares had fallen 4.07% on Wednesday to Rs 594.50 following the block transaction, but rebounded on Thursday as investor interest in the stock remained firm. ADVERTISEMENT Also read | Carlyle group exits Indegene; sells 10.2% stake for Rs 1,447 crore (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel) Nikita Papers IPO opens on May 27, price band set at Rs 95-104 per share Nikita Papers IPO opens on May 27, price band set at Rs 95-104 per share Why gold prices could surpass $4,000: JP Morgan's bullish outlook explained Why gold prices could surpass $4,000: JP Morgan's bullish outlook explained Cyient shares fall over 9% after Q4 profit declines, core business underperforms Cyient shares fall over 9% after Q4 profit declines, core business underperforms L&T Technology Services shares slide 7% after Q4 profit dips L&T Technology Services shares slide 7% after Q4 profit dips Trump-Powell standoff puts U.S. Rate policy in crosshairs: Who will blink first? Trump-Powell standoff puts U.S. Rate policy in crosshairs: Who will blink first? SEBI warns of securities market frauds via YouTube, Facebook, X and more SEBI warns of securities market frauds via YouTube, Facebook, X and more API Trading for All: Pi42 CTO Satish Mishra on How Pi42 is Empowering Retail Traders API Trading for All: Pi42 CTO Satish Mishra on How Pi42 is Empowering Retail Traders Security, transparency, and innovation: What sets Pi42 apart in crypto trading Security, transparency, and innovation: What sets Pi42 apart in crypto trading Bitcoin, Ethereum, or Altcoins? How investors are structuring their crypto portfolios, Avinash Shekhar explains Bitcoin, Ethereum, or Altcoins? How investors are structuring their crypto portfolios, Avinash Shekhar explains The rise of Crypto Futures in India: Leverage, tax efficiency, and market maturity, Avinash Shekhar of Pi42 explains NEXT STORY
Time of India
05-06-2025
- Business
- Time of India
Sunil Singhania picks stake in Indegene, stock up 4%
Shares of Indegene Ltd rose as much as 3.7% to Rs 611.50 on the BSE on Thursday, a day after Sunil Singhania 's Abakkus Emerging Opportunities Fund picked up a stake in the company through a large block deal. Abakkus was among several institutional investors that bought shares in the transaction where private equity major Carlyle Group exited its entire 10.2% holding in the digital healthcare firm. A total of 2.53 crore shares, amounting to 10.56% of Indegene's equity, changed hands on Wednesday, June 4, at an average price of Rs 591 apiece, according to exchange data released Thursday. Carlyle, through its unit CA Dawn Investments, was the sole seller in the deal, garnering Rs 1,447 crore from the divestment. Who bought? Alongside Abakkus, other buyers included East Bridge Capital Master Fund, Societe Generale, Smallcap World Fund, and Premji Invest's affiliate PI Opportunities AIF V. Together, these investors picked up 1.06 crore shares, or 4.42% stake, for Rs 627 crore. The shares were acquired in the price range of Rs 591–591.48 each. Details of other buyers were not available on the National Stock Exchange as of Thursday. Carlyle's phased exit Carlyle's exit marks the end of a four-year investment in Indegene. The global private equity firm had invested $122 million (Rs 917 crore) in April 2021, purchasing 4.55 crore shares at Rs 201 apiece. Since then, it has sold shares in phases, first during Indegene's IPO in May 2024 at Rs 452 apiece, then at Rs 618 in December 2024, and finally at around Rs 591 this week. The investment delivered an internal rate of return of 31% for Carlyle, underscoring the strong returns possible in India's digital healthcare sector. Indegene's shares had fallen 4.07% on Wednesday to Rs 594.50 following the block transaction, but rebounded on Thursday as investor interest in the stock remained firm. Also read | Carlyle group exits Indegene; sells 10.2% stake for Rs 1,447 crore ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
